pharma · IgA Nephropathy · Rhematoid Arthritis · JBIO
Jade Biosciences
Jade Biosciences is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker JBIO. Primary therapeutic focus areas include IgA Nephropathy, Rhematoid Arthritis. NovaPharmaNews links 4 clinical
Waltham, USA HQ
2024 Founded
72 Employees
Public company Type
JBIO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2024
- Employees
- 72
- Programs
- 4
- Drugs
- 1
- Patents
- 2
JADE101
Phase 2 · small molecule · IgA Nephropathy
JADE101 for IgA Nephropathy is a Phase 2 program (small_molecule) at Jade Biosciences with 1 ClinicalTrials.gov record(s).
Internal code JADE101-02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Jade Biosciences
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- IgA Nephropathy
- Status
- active
- Trials
- 1